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Edited by Lukas HuberAbstract We have earlier reported overexpression of the cen-
tral and peripheral cannabinoid receptors CB1 and CB2 in man-
tle cell lymphoma (MCL), a B cell non-Hodgkin lymphoma. In
this study, treatment with cannabinoid receptor ligands caused
a decrease in viability of MCL cells, while control cells lacking
CB1 were not aﬀected. Interestingly, equipotent doses of the
CB1 antagonist SR141716A and the CB1/CB2 agonist ananda-
mide inﬂicted additive negative eﬀects on viability. Moreover,
treatment with the CB1/CB2 agonist Win-55,212-2 caused a de-
crease in long-term growth of MCL cells in culture. Induction of
apoptosis, as measured by FACS/Annexin V–FITC, contributed
to the growth suppressive eﬀect of Win-55,212-2. Our data sug-
gest that cannabinoid receptors may be considered as potential
therapeutic targets in MCL.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Mantle cell lymphoma (MCL) is an essentially incurable
non-Hodgkin lymphoma of B cell type that is characterized
by short remissions and poor prognosis [1]. Recently, highly
increased expression of the central cannabinoid receptor
type 1 (CB1) and moderately increased expression of can-
nabinoid receptor type 2 (CB2) was reported in MCL
[2,3]. In brain, CB1 mediates the eﬀect of delta9-tetrahydro-
cannabinol, the active metabolite of cannabis. In contrast to
CB2, CB1 is normally expressed at low levels in immune
cells, rev. in [4]. Most naturally occurring ligands, the so-
called endocannabinoids, act on both receptors [4]. Several
studies have shown that both natural and synthetic cannab-
inoids may induce growth arrest and apoptosis in cell linesAbbreviations: MCL, mantle cell lymphoma; CB1, cannabinoid recep-
tor type 1; CB2, cannabinoid receptor type 2; Win-55,212-2, (R)-(+)-
Win-55,212-2 (2,3 dihydro)-5-methyl-3 [(morpholinyl)-methyl]pyrollo
(1,2,3 de)-1,4-benzoxazinyl]-[1-naphthaleny]methanone; anandamide,
arachidonic acid N-(hydroxyethyl)amide; DAPI, 4 0,6-diamidino-2-
phenylindole; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetra-
zolium bromide; PI, propidium iodide
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doi:10.1016/j.febslet.2005.11.020of widely diﬀerent origin (rev. in [5]) [6]. In contrast, other
reports have suggested that low doses of cannabinoids may
actually enhance proliferation of malignant and normal cells
[7,8]. Ligation of CB1 receptors might also aﬀect non-malig-
nant immunocompetent cells, either directly or via accessory
cells. Cannabinoids have been shown to modulate both T
cell responses [9] and the production of cytokines in macro-
phages and dendritic cells [10]. Not only agonists to can-
nabinoid receptors, but also antagonists alone have
recently been reported to inhibit growth [11] or induce
apoptosis in cancer cells [12,13]. In addition to their role
as antagonists, these substances have been reported to block
the constitutive, low level signalling through CB-receptors,
thereby acting as inverse agonists, rev. in [18]. In this study,
we have investigated the eﬀects of treatment with cannabi-
noid receptor agonists and antagonists on viability and
growth of MCL cells. Our results show that cannabinoid
receptor ligands mediate inhibition of growth and survival
of MCL cells, and that these eﬀects in part are mediated
by induction of apoptosis.2. Materials and methods
2.1. Reagents
DMEM, RPMI-1640, fetal bovine serum and gentamicin were pur-
chased from Life Technologies, Invitrogen Corporation (Grand Is-
land, NY), rabbit polyclonal antibody to CB1 (ab3559) from
Abcam (United Kingdom), anti-rabbit Ig horseradish peroxidase
linked antibody from Amersham Biosciences (United Kingdom),
Cy3 conjugated donkey-anti-rabbit antiserum from Jackson Immuno-
Research (West grove, PA), PVDF membrane from Millipore (Bed-
ford, MA), Supersignal West Pico chemiluminescent substrate
from Pierce Biotechnology (Rockford, IL), 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay from Roche
Diagnostics (Germany), Annexin V kit from Caltag Laboratories
(Burlingame, CA) DMSO, G418, formaldehyde, BSA, Saponin,
p8340, G418, 4 0,6-diamidino-2-phenylindole (DAPI), (R)-(+)-Win-
55,212-2 (2,3 dihydro)-5-methyl-3 [(morpholinyl)-methyl]pyrollo
(1,2,3 de)-1,4-benzoxazinyl]-[1-naphthaleny]methanone and arachi-
donic acid N-(hydroxyethyl)amide (anandamide) from Sigma–Aldrich
(St. Louis, MO), AM 251 from Tocris (Avonmouth, Bristol, United
Kingdom), SR141716A was a generous gift from Sanoﬁ-Reserche
(Montpellier, France). The CB1/CB2 ligands were dissolved to
10 mM in DMSO or 70% ethanol and further diluted in culture
medium at the day of the experiment.
2.2. Tumor tissue
Tumor tissues from diagnostic biopsies from 15 patients with MCL
were investigated by morphology, ﬂow cytometry and by IHC for cy-
clin D1. In all cases t(11;14) translocation was conﬁrmed by FISHblished by Elsevier B.V. All rights reserved.
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This study was approved by the Ethics Committee at Karolinska Insti-
tutet (Etikkommitte´ Syd).2.3. Cell culture
Single cell suspensions from biopsies were frozen in DMSO and
stored at 120 C. At the day of the experiment, the cells were thawn
and cultured at 1 · 106/ml in RPMI-1640. The EBV transformed MCL
cell line Rec-1, the plasma cell leukaemia cell line SK-MM-2, the
AtT20 cell line transfected with cDNA for the rat CB1 receptor
(AtT20-CB1) and AtT20-wt were obtained and treated as described
[3]. The breast cancer cell line MCF7 was cultured in DMEM. Cell cul-
tures were maintained in medium supplemented with 50 lg/ml genta-
micin and 10% fetal calf serum. Experiments were performed at the
indicated serum concentrations.2.4. RNA isolation, oligonucleotide array hybridization and gene
expression analysis
Total RNA was prepared and hybridizations were performed using
U133A arrays (Aﬀymetrix, Inc, Santa Clara, CA) as described in [3].
The data were analyzed using Aﬀymetrix Micro array Suite version
5.0. Comparative analyses were performed using Aﬀymetrix Datamin-
ing Tool version 3.0.2.5. Western blotting
Cell extracts were prepared using ice-cold lysis buﬀer (50 mM
HEPES, 500 mM NaCl, 0.05% Tween 20, 0.1% Triton X-100) to
which protease inhibitor cocktail p8340 had been added. Proteins
(40 lg/lane) were resolved by 10% SDS–PAGE and transferred onto
PVDF membrane, which was incubated with a rabbit polyclonal
antibody to CB1. Antibody binding was detected by enhanced
chemiluminescence using Supersignal West Pico chemiluminescent
substrate.Table 1
Expression of CB1 and CB2 and in primary MCL and cell lines as
described in [3]a, present publicationb (gene expression array signal
value for CB1 in Rec-1 was 124 and in SK-MM was an absent call;
signal value for CB2 in Rec-1 was 83 and in SK-MM was 46), [20]c and
[21]d
Cell lines CB1 CB2
RNA2.6. Cell viability
Viability of cells treated with CB1/CB2 ligands dissolved to
10 mM in DMSO or 70% ethanol (anandamide) was determined
by cell counting (trypan blue exclusion) or using the MTT assay
according to the manufacturers instructions. Absorbance was mea-
sured at 570 nm and reported as optical density (OD). Percent via-
bility is calculated as 100 * OD treated cells (mean of three
individually treated wells)/OD vehicle-treated cells (mean of three
individually treated wells).
2.7. Cell growth
0.75 million Rec-1 cells/ml were cultured in medium containing 10%
fetal calf serum. Indicated doses of Win-55,212-2 or SR141716A were
added to duplicate cultures. An equal concentration of DMSO was
maintained in each ﬂask. The cells were either counted after three days
or every second day. In the latter case, 0.75 million cells/ml were seeded
again and treated as described above. The theoretical total number of
cells deriving from the original ﬂask was calculated every second day
until the end of the experiment at day eight.RNA Protein
Primary MCL +a +a +a
Rec-1 +b +b +b
SK-MM b a +b
AtT20-CB1 +++a,c
AtT20-wt +b
MCF7 +d +d +d
Fig. 1. Protein expression of CB1 in SK-MM-2 and Rec-1. Western
blot analysis of CB1 protein expression in whole cell extracts of the
plasma cell line SK-MM-2 (left) and the MCL cell line Rec-1 (right).2.8. Apoptosis and ﬂow cytometric analysis
Rec-1 cells growing exponentially in 10% serum were treated with
10 lM Win-55,212-2 and harvested 24 h after the treatment. The cells
were labeled with Annexin V–FITC and propidium iodide (PI) using
the Annexin V kit according to the manufacturers instructions. Subse-
quent ﬂowcytometric analysis was performed on a FACScan (Becton
Dickinson, Mountain View, CA). Fluorescence data were displayed
as dot plots using the Cell Quest software (Becton Dickinson, Franklin
Lakes, NJ).
2.9. Statistical analysis
Cell viability and growth was compared using Kruskal–Wallis test
between vehicle-treated cells and cells treated with CB1/CB2 ligands.
P-values smaller than 0.05 were considered signiﬁcant. The software
Statistica (StatSoft Scandinavia AB, Tulsa, OK) was used.3. Results and discussion
3.1. Expression of CB1 and CB2 in primary MCL and in cell
lines
Results of expression analysis of CB1 and CB2 in the present
and earlier studies are summarized in Table 1. Western blot-
ting (Fig. 1) showed high levels of CB1 protein in Rec-1, while
no expression was detectable in SK-MM-2.
3.2. Eﬀect of CB1/CB2 ligands on viability of primary MCL
cells and cell lines
To investigate the eﬀect of cannabinoid receptor ligands on
viability, freshly isolated MCL cells were cultured in the pres-
ence of the endocannabinoid anandamide or the synthetic
high-eﬃcacy cannabinoid Win-55,212-2. Both substances are
non-selective cannabinoid receptor ligands with aﬃnity for
both CB1 and CB2, rev. in [4]. Five lM of either agent de-
creased cell viability measured as trypan blue exclusion 24 h
after treatment (Fig. 2A). The eﬀect was more pronounced at
lower serum concentrations, as expected from earlier studies
[14,15]. Therefore, the next experiment using the CB1 antago-
nist SR141716A was performed at 0.5% serum. SR141716A
alone reduced the viability of MCL cells isolated from tumor
biopsies of two patients (L144 and L102) (Fig. 2B). Thus, liga-
tion with both agonists to CB1/CB2 and an antagonist to CB1
caused decreased viability in primary MCL cells.
Earlier studies in breast cancer [16] and prostate cancer cell
lines [6] have shown that antiproliferative and growth inhibi-
tory eﬀects of anandamide could be antagonized by
SR141617A. However, potentiation of anandamide-mediated
cell death by preincubation with these antagonists has also
been reported [17]. In view of the conﬂicting observations,
we wanted to investigate the eﬀects of combined treatment
with SR141716A and anandamide in MCL cells. In these stud-
ies, the MCL cell line Rec-1 was used. Only at a low dose
(0.5 lM) of SR141716A a slight antagonizing eﬀect was ob-
served in Rec-1 cells treated with 5 lM of anandamide
(Fig. 3A). Instead, an additive negative eﬀect on viability
was observed after treatment with equipotent doses (5 lM)
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Fig. 2. Viability of MCL cells in response to treatment with CB1/CB2
ligands. (A) Primary MCL cells freshly isolated from a diagnostic
tumor biopsy treated with anandamide (5 lM) or Win-55,212-2 (5 lM)
in the presence of the indicated serum concentrations. Cell viability
was measured 24 h after treatment using trypan blue exclusion.
Viability of treated cells is expressed as percent of vehicle-treated
control and based on the mean value of four individual treatments.
Error bars indicate standard deviations. *, P < 0.05 compared to
control for anandamide at 1% and 0.5% serum and for Win-55,212-2 at
0.5% serum, Kruskal–Wallis test. (B) Titration of the CB1 antagonist
SR141716A on primary MCL cells from tumor biopsies of two
patients (L144 and L102). The cells were treated and cultured in the
presence of 0.5% serum. Cell viability was measured 24 h after
treatment using trypan blue exclusion. Viable cells ·106 are shown.
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Fig. 4. Viability of cell lines with diﬀerent CB1 expression in response
to CB1/CB2 ligands. (A) Rec-1 cells with high CB1 expression and SK-
MM-2 with no detectable CB1 expression. (B) AtT20-CB1 with high
ectopic CB1 expression and AtT20-wt with low endogenous CB1
expression. The cells were cultured in the presence of 10% serum and
treated with the CB1/CB2 agonist anandamide. The MTT assay was
performed 48 h after treatment. Viability of treated cells is expressed as
percent of vehicle-treated control and based on the mean value of three
individual treatments. Error bars indicate standard deviations. *,
P < 0.05 compared with control, Kruskal–Wallis test.
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earlier described antagonizing eﬀect of SR141716A [16] was
conﬁrmed in the breast cancer cell line MCF7 (Fig. 3B).0
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Fig. 3. Eﬀect of the CB1 receptor antagonist SR141716A on reduction o
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1% serum were treated with 0 or 1 lM of the CB1/CB2 agonist anandamide aSR141716A has, in addition to its antagonizing eﬀect, been
shown to act as an inverse agonist to both CB1 and CB2
[18]. Such a role could possibly explain our observed additive
eﬀect of combined treatment with SR141716A and ananda-
mide or Win-55,212-2 in MCL.
In order to elucidate the role of CB1 as a mediator of the ob-
served eﬀects, additional studies of cell viability were per-
formed using SK-MM-2, a cell line of B cell origin that does
not express CB1 (Fig. 1), as a control. SK-MM-2 harbors a
Cyclin D1 t(11;14) translocation similar to that observed in
Rec-1. The experiments were performed at 10% serum, a con-
centration that allows long-term studies of cell growth in cul-
ture. Forty-eight hours after treatment with 10 lM of
anandamide, cell viability was signiﬁcantly reduced in Rec-1
cells, whereas SK-MM-2 cells remained unaﬀected (Fig. 4A).
Similarly, a selective reduction of viability in response to
anandamide was observed in AtT20 cells transfected with
CB1 [19] (Fig. 4B). These results suggest that CB1 is involved
in the viability reduction induced by anandamide in MCL
cells, although a role of CB2 cannot be excluded.0
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Fig. 6. Induction of apoptosis in Rec-1 following treatment with Win-
55,212-2. Flow cytometry analysis of Annexin V–FITC and PI 24 h
after treatment of Rec-1 cells with 10 lMWin-55,212-2 in the presence
of 10% serum. One representative cytogram showing early apoptotic
cells that bind to Annexin V–FITC but exclude PI, lower right-hand
quadrant (LR), and late apoptotic/necrotic cells that bind to both
Annexin V–FITC and PI, upper right-hand quadrant (UR). The
6888 J. Flygare et al. / FEBS Letters 579 (2005) 6885–68893.3. Eﬀect of Win-55,212-2 on growth of Rec-1 cells
Next, the eﬀect of treatment with a CB1/CB2 agonist or a
CB1 antagonist on long-term growth of Rec-1 cells was
studied. Win-55,212-2, which is a more stable agonist than
anandamide, was chosen for this experiment. Previously re-
ported short-term studies at low serum concentration have
suggested pro-proliferative eﬀects of treatment with CB1/
CB2 agonists in the nanomolar range [7,8,11]. However,
when Rec-1 cells were cultured in the presence of Win-
55,212-2 for 3 days, 10 and 100 nM of the agonist caused
a slight growth inhibition (Fig. 5A). When growth was stud-
ied for 8 days, 1 lM of Win-55,212-2 caused a considerable
decrease in the accumulated number of cells at the end of
the period. A similar reduction in growth was observed in
response to 10 lM of SR141716A (Fig. 5B). Thus, at 10%
serum, a low dose of the CB1/CB2 agonist Win-55,2121-2
caused substantial growth suppression in Rec-1 cells, while
a 10-fold higher dose of the CB1 antagonist SR141716A
was required for similar eﬀects.0 0.01 0.1 1 10 µM
Win55,212-2
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Fig. 5. Eﬀects of the CB1/CB2 agonist Win-55,212-2 on growth of
Rec-1 cells. (A) Rec-1 cells cultured in the presence of 10% serum and
treated with the indicated concentrations of Win-55,212-2 for three
days. Viability of treated cells is expressed as percent of vehicle-treated
control and based on the mean value of two individually treated
cultures. Error bars indicate highest and lowest value. (B) Long-term
growth of Rec-1 cells cultured in the presence of 10% serum and
treated with the indicated doses of Win-55,212-2 or the CB1 antagonist
SR141716A. The percentage of the accumulated number of treated
cells versus the accumulated number of control cells during eight days
of culturing in the presence of 10% serum is shown. The accumulated
growth is based on the mean value of two individually treated cultures.
For the sake of clarity, error bars are omitted in the graph.
experiment was performed in duplicate.3.4. Eﬀect of Win-55,212-2 on apoptosis of Rec-1 cells
To determine whether treatment with Win-55,212-2 at 10%
serum would lead to induction of apoptosis in Rec-1, the cells
were labeled with Annexin V and PI and analyzed by ﬂow
cytometry. Twenty-four hours after treatment with 10 lM of
Win-55,212-2, the fraction of early apoptotic cells was 8.3%
as compared to 2.8% in the control culture (Fig. 6). The sum
of the fractions of early (8.3%) and late (3.2%) apoptotic/ne-
crotic cells was 11.5% in the Win-55,212-2 treated culture ver-
sus 3.9% (2.8% + 1.1%) in the control culture. Our results
show that apoptosis accounts for part of the decreased cell
growth observed in Rec-1 cells treated with Win-55,212-2.
However, other factors, e.g., alterations in cell cycle progres-
sion, might contribute to the growth inhibition.
In conclusion, we have found that cannabinoid receptor li-
gands induce decreased viability, growth suppression and cell
death by apoptosis in MCL cells, which express high levels of
the CB1 receptor and moderate levels of CB2. The current re-
sults in vitro suggest that CB1/CB2 ligands should be considered
as agents for the treatment of MCL. In vivo conﬁrmation of the
growth-suppressive eﬀects of cannabinoids on MCL cells and
investigations of possible eﬀects on non-malignant immuno-
competent cells will further elucidate the potential of cannabi-
noid receptors as targets of therapy in mantle cell lymphoma.
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